{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T13:55:47Z","timestamp":1781013347972,"version":"3.54.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jaccao.2024.02.003","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T18:47:10Z","timestamp":1713293230000},"page":"200-213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Impact of Preexisting Heart\u00a0Failure on Treatment and Outcomes in Older Patients With Hodgkin Lymphoma"],"prefix":"10.1016","volume":"6","author":[{"given":"Jenica N.","family":"Upshaw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Sweigart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angie Mae","family":"Rodday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita J.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marvin A.","family":"Konstam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Ky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Karmiy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Evens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Kent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan K.","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jaccao.2024.02.003_bib2","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","article-title":"Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk","volume":"175","author":"van Nimwegen","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1016\/j.jaccao.2024.02.003_bib3","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1200\/JCO.21.02613","article-title":"Development and validation of risk prediction models for coronary heart disease and heart failure after treatment for Hodgkin lymphoma","volume":"41","author":"de Vries","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"35","key":"10.1016\/j.jaccao.2024.02.003_bib4","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1200\/JCO.20.00264","article-title":"Cause-specific mortality following initial chemotherapy in a population-based cohort of patients with classical Hodgkin lymphoma, 2000-2016","volume":"38","author":"Dores","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2024.02.003_bib5","series-title":"Surveillance, Epidemiology, and End Results. Cancer statistics","year":"2022"},{"issue":"30","key":"10.1016\/j.jaccao.2024.02.003_bib6","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2018.79.0139","article-title":"Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma","volume":"36","author":"Evens","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"10.1016\/j.jaccao.2024.02.003_bib7","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1182\/bloodadvances.2021004645","article-title":"Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma","volume":"5","author":"Orellana-Noia","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaccao.2024.02.003_bib8","first-page":"CD014638","article-title":"Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines","volume":"9","author":"de Baat","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.jaccao.2024.02.003_bib9","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1200\/JCO.1997.15.4.1318","article-title":"Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer","volume":"15","author":"Swain","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.jaccao.2024.02.003_bib10","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/annonc\/mdj134","article-title":"Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced\/metastatic breast cancer patients treated with anthracycline-based chemotherapy","volume":"17","author":"Marty","year":"2006","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.jaccao.2024.02.003_bib11","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/00001813-200606000-00014","volume":"17","author":"Batist","year":"2006","journal-title":"Anticancer Drugs"},{"issue":"3","key":"10.1016\/j.jaccao.2024.02.003_bib12","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O\u2019Brien","year":"2004","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.jaccao.2024.02.003_bib13","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1080\/10428194.2019.1608529","article-title":"Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (>\/=70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL)","volume":"60","author":"Salvi","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.jaccao.2024.02.003_bib14","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/bjh.18348","article-title":"Liposomal doxorubicin supercharge-containing front-line treatment in patients with advanced-stage diffuse large B-cell lymphoma or classical Hodgkin lymphoma: Preliminary results of a single-centre phase II study","volume":"198","author":"Picardi","year":"2022","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.jaccao.2024.02.003_bib15","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1200\/JOP.2016.018770","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline summary","volume":"13","author":"Armenian","year":"2017","journal-title":"J\u00a0Oncol Pract"},{"issue":"5","key":"10.1016\/j.jaccao.2024.02.003_bib16","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1001\/jamacardio.2023.0303","article-title":"Association of preexisting heart failure with outcomes in older patients with diffuse large B-cell lymphoma","volume":"8","author":"Upshaw","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"8","key":"10.1016\/j.jaccao.2024.02.003_bib17","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"issue":"17","key":"10.1016\/j.jaccao.2024.02.003_bib18","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1001\/jama.296.17.2105","article-title":"Statin therapy and risks for death and hospitalization in chronic heart failure","volume":"296","author":"Go","year":"2006","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jaccao.2024.02.003_bib19","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1093\/aje\/kwx257","article-title":"External validation of the claims-based frailty index in the national health and aging trends study cohort","volume":"186","author":"Segal","year":"2017","journal-title":"Am J Epidemiol"},{"issue":"2","key":"10.1016\/j.jaccao.2024.02.003_bib20","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/aje\/kwp107","article-title":"Competing risk regression models for epidemiologic data","volume":"170","author":"Lau","year":"2009","journal-title":"Am J Epidemiol"},{"issue":"11","key":"10.1016\/j.jaccao.2024.02.003_bib21","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1002\/sim.2712","article-title":"Tutorial in biostatistics: competing risks and multi-state models","volume":"26","author":"Putter","year":"2007","journal-title":"Stat Med"},{"issue":"10","key":"10.1016\/j.jaccao.2024.02.003_bib22","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.28373","article-title":"Association of treatment intensity with survival in older patients with Hodgkin lymphoma","volume":"4","author":"Rodday","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"22","key":"10.1016\/j.jaccao.2024.02.003_bib23","doi-asserted-by":"crossref","first-page":"5924","DOI":"10.1182\/bloodadvances.2022008258","article-title":"The outcome of older adults with classic Hodgkin lymphoma in British Columbia","volume":"6","author":"Cheng","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.jaccao.2024.02.003_bib24","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.clml.2023.01.014","article-title":"Characteristics and outcomes of older patients with classical Hodgkin lymphoma: an Australasian Lymphoma Alliance, and Lymphoma and Related Diseases Registry study","volume":"23","author":"Goh","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"20","key":"10.1016\/j.jaccao.2024.02.003_bib25","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1182\/blood-2017-05-736975","article-title":"Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma","volume":"130","author":"Lin","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jaccao.2024.02.003_bib26","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/ejh.12608","article-title":"Analysis of elderly patients with diffuse large B-cell lymphoma: aggressive therapy is a reasonable approach for \u201cunfit\u201d patients classified by comprehensive geriatric assessment","volume":"96","author":"Yoshida","year":"2016","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.jaccao.2024.02.003_bib27","first-page":"292","article-title":"Cardioprotection in patients at high risk of anthracycline-induced cardiotoxicity: JACC: CardioOncology primer","volume":"5","author":"Henriksen","year":"2023","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jaccao.2024.02.003_bib28","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejca.2016.02.004","volume":"58","author":"Fridrik","year":"2016","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.jaccao.2024.02.003_bib29","first-page":"302","article-title":"Permissive cardiotoxicity: the clinical crucible of cardio-oncology","volume":"4","author":"Porter","year":"2022","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"issue":"26","key":"10.1016\/j.jaccao.2024.02.003_bib30","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/blood-2017-06-787200","article-title":"Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged >\/=60 years with HL","volume":"130","author":"Friedberg","year":"2017","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.jaccao.2024.02.003_bib31","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.jaccao.2024.02.003_bib32","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jamaoncol.2020.0750","article-title":"Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL trial","volume":"6","author":"Brockelmann","year":"2020","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.jaccao.2024.02.003_bib33","doi-asserted-by":"crossref","first-page":"e808","DOI":"10.1016\/S2352-3026(20)30275-1","article-title":"Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial","volume":"7","author":"Cheson","year":"2020","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.jaccao.2024.02.003_bib34","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.cardfail.2022.02.009","article-title":"2022 American College of Cardiology\/American Heart Association\/Heart\u00a0Failure Society of America guideline for the management of heart failure: executive summary","volume":"28","author":"Heidenreich","year":"2022","journal-title":"J\u00a0Card Fail"},{"issue":"10","key":"10.1016\/j.jaccao.2024.02.003_bib35","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.jacc.2019.03.009","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jaccao.2024.02.003_bib36","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","volume":"74","author":"January","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jaccao.2024.02.003_bib37","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.jtcvs.2014.11.002","volume":"149","author":"Fihn","year":"2015","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"issue":"4","key":"10.1016\/j.jaccao.2024.02.003_bib38","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.jaccao.2024.02.003_bib39","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jaccao.2024.02.003_bib40","doi-asserted-by":"crossref","unstructured":"Bozkurt B, Coats AJ, Tsutsui H, et\u00a0al. Universal definition and classification of heart failure: a report of the Heart\u00a0Failure Society of America, Heart\u00a0Failure Association of the European Society of Cardiology, Japanese Heart\u00a0Failure Society and Writing Committee of the Universal Definition of Heart\u00a0Failure. J Card Fail. 2021;27(4):387-413.https:\/\/doi.org\/10.1016\/j.cardfail.2021.01.022.","DOI":"10.1016\/j.cardfail.2021.01.022"}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087324000565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087324000565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:21:42Z","timestamp":1734567702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666087324000565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S2666087324000565"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2024.02.003","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Preexisting Heart\u00a0Failure on Treatment and Outcomes in Older Patients With Hodgkin Lymphoma","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2024.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}